Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464216 | 1.00 | SIGMAR1 (0.37) | SIGMAR1ALDH1A1HRH3SLC9A1HDAC4 | |
| SCHEMBL6943629 | 0.86 | SIGMAR1 (0.37) | SIGMAR1ALDH1A1HRH3CHRNA7GPR88 | |
| SCHEMBL7206322 | 0.77 | CA1 (0.36) | HDAC4CA12CA1CA2CA9 | |
| SCHEMBL7211822 | 0.76 | STS (0.40) | SMN1; SMN2MAPTCA12CA1CA2 | |
| SCHEMBL7206852 | 0.75 | CA12 (0.37) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL7207611 | 0.75 | CA1 (0.37) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL8497715 | 0.75 | FAAH (0.37) | CA12CA1CA2CA9 | |
| SCHEMBL8498058 | 0.74 | ATM (0.39) | ALDH1A1HDAC4SMN1; SMN2TDP1MAPT | |
| SCHEMBL7207511 | 0.74 | STS (0.48) | MAPTHPGDCA12CA1CA2 | |
| SCHEMBL7206838 | 0.74 | CA1 (0.37) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155832-A1 | Use of sulfonamide compounds for the treatment of diabetes and/or obesity | ASTRAZENECA AB (SE) | 2007-07-05 | — | — | US | claimed |
| EP-1682112-A1 | USE OF SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND/OR OBESITY | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | claimed |
| WO-2005044250-A1 | USE OF SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND/OR OBESITY | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | claimed |
| US-20030134898-A1 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | HOMAN REYNOLD (US) | 2003-07-17 | — | — | US | claimed |
| JP-2003513909-A | — | — | 2003-04-15 | — | — | JP | claimed |
| EP-0841913-B1 | USE OF SULFAMIC ACID DERIVATIVES, ACYL SULFONAMIDES OR SULFONYL CARBAMATES FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING LIPOPROTEIN LEVELS | WARNER LAMBERT CO (US) | 2003-02-05 | — | — | EP | claimed |
| EP-1281399-A2 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | WARNER-LAMBERT COMPANY (US) | 2003-02-05 | — | — | EP | claimed |
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | claimed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| US-6117909-A | TREATING CARDIOVASCULAR DISEASE SUCH AS STROKE, PERIPHERAL VASCULAR DISEASES, AND RESTENOSIS. | WARNER-LAMBERT COMPANY (US) | 2000-09-12 | — | — | US | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0698010-B1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER LAMBERT CO (US) | 1999-04-14 | — | — | EP | claimed |
| EP-0841913-A1 | USE OF SULFAMIC ACID DERIVATIVES, ACYL SULFONAMIDES OR SULFONYL CARBAMATES FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING LIPOPROTEIN LEVELS | WARNER-LAMBERT COMPANY (US) | 1998-05-20 | — | — | EP | claimed |
| WO-1997005868-A1 | USE OF SULFAMIC ACID DERIVATIVES, ACYL SULFONAMIDES OR SULFONYL CARBAMATES FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING LIPOPROTEIN LEVELS | WARNER-LAMBERT COMPANY (US) | 1997-02-20 | — | — | WO | claimed |
| EP-0698010-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-28 | — | — | EP | claimed |
| US-5491172-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1996-02-13 | — | — | US | claimed |
| WO-1994026702-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-11-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | NFKBIA, IKBKB, RELA | SIGMAR1 4754/4885ALDH1A1 4328/4885HRH3 2535/4885 |
| US-20030134898-A1 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | ACAT2, LCAT, SOAT1 | SIGMAR1 2461/4885ALDH1A1 412/4885HRH3 2626/4885 |
| US-20070155832-A1 | Use of sulfonamide compounds for the treatment of diabetes and/or obesity | GPR119, DGAT1, DGAT2 | SIGMAR1 100/4885ALDH1A1 521/4885HRH3 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.